Happy New Year and welcome to 2022. Here is your research news for January. Stay up to date on monthly research updates with us! Sanguine is currently recruiting for 51 research studies. Check out the latest Sanguine studies here.
COVID-19 Omicron Antibodies: The COVID-19 omicron variant contains many mutations, which is why it’s been able to evade many of the existing vaccines and treatments. However, researchers at the Washington School of Medicine have found antibodies that target the coronavirus spike protein and may help protect against the omicron variant and other mutations.
COVID-19 and Vitamin D: A new study conducted in part by the National Institute of Health (NIH) reveals that a certain form of vitamin D (an active metabolite that’s not available OTC) may play a role in switching off inflammation in infections like COVID-19. Inflammation is a “key reason for morbidity and mortality in COVID-19.”
COVID-19 Effects in Children: As past of the RECOVER Initiative, the NIH will be launching a 3 year study to evaluate the long-term effects of COVID-19 on children. The study will track 1,000 children who previously were infected with COVID-19 to determine the effects of the infection on physical and mental health.
Sickle Cell Disease Research News Updates
Saying NO with SCD: Navigating sickle cell disease can be challenging and avoiding crises can be a full time-job. This blogger emphasizes the importance of knowing your boundaries and saying no to prioritize your health.
$15 Million for Sickle Cell Disease: The Georgia Research Alliance is launching a 5-year $15 million campaign to develop new treatments for sickle cell disease. The Alliance is a nonprofit public-private partnership that includes 8 universities and medical schools.
Lupus Research News Updates
Lupus and HCQ: According to a new research study, hydroxychloroquine (HCQ) treatment maintenance is important for those with lupus. Patients who decreased HCQ dosage or stopped taking the treatment altogether were more likely to experience disease flares compared to those who maintained treatment.
LUPKYNIS for Lupus Nephritis: This past month Aurinia Pharmaceuticals released findings from clinical trials in favor of Lupkynis (voclosporin) as a treatment for lupus nephritis. The study demonstrates the safety and efficacy of the treatment over a 3 year period. Lupkynis was the first FDA approved treatment for lupus nephritis.
Related Story
